Immunomodulator effect of picroliv and its potential in treatment against resistant Plasmodium yoelii (MDR) infection in mice

被引：7

作者：

Dwivedi, Varun ^{[1
]}

Khan, Arif ^{[2
]}

Vasco, Azevedo ^{[3
]}

Fatima, Nishat ^{[2
]}

Soni, Vishal Kumar ^{[4
]}

Dangi, Anil ^{[4
]}

Misra-Bhattacharya, Shailja ^{[4
]}

Owais, Mohammad ^{[2
]}

机构：

[1] Aligarh Muslim Univ, Dept Biochem, JN Med Coll, Aligarh, Uttar Pradesh, India

[2] Aligarh Muslim Univ, Inter Disciplinary Biotechnol Unit, Aligarh 202002, Uttar Pradesh, India

[3] Univ Fed Minas Gerais, ICB, Depto Biol Geral, BR-6627 Belo Horizonte, MG, Brazil

[4] Cent Drug Res Inst, Dept Parasitol, Lucknow 226001, Uttar Pradesh, India

来源：

PHARMACEUTICAL RESEARCH | 2008年 / 25卷 / 10期

关键词：

chloroquine; immunomodulator; malaria; picroliv;

D O I：

10.1007/s11095-008-9631-2

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Purpose. The present study was envisaged to evaluate potential of combination therapy comprising of immunomodulator picroliv and antimalarial chloroquine against drug resistant Plasmodium yoelii (P. yoelii) infection in BALB/c mice. Methods. The immunomodulatory potential of picroliv was established by immunizing animals with model antigen along with picroliv. Immune response was assessed using T-cell proliferation assay and also by determining the antibody isotype-profile induced in the immunized mice. In the next set of experiment, prophylactic potential of picroliv to strengthen antimalarial properties of chloroquine against P. yoelii (MDR) infection in BALB/c mice was assessed. Results. T-cell proliferation as well as antibody production study reveals that picroliv helps in evoking strong immuno-potentiating response against model antigen in the immunized mice. Co-administration of picroliv enhances efficacy of CHQ against experimental murine malaria. Conclusion. The activation of host immune system can increase the efficacy of chloroquine for suppression of drug resistant malaria infection in BALB/c mice.

引用

页码：2312 / 2319

页数：8

共 33 条

[11]

DWIVEDI Y, 1992, PHARMACOL TOXICOL, V71, P1

[12] Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis [J].

Gupta, S ;

Ramesh ;

Sharma, SC ;

Srivastava, VML .

ACTA TROPICA, 2005, 94 (01) :41-47

[13]

HUNTER RL, 1995, J IMMUNOL, V154, P1762

[14] Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice [J].

Khan, MA ;

Khan, A ;

Owais, M .

FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2006, 46 (01) :63-69

[15] Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB/c mice [J].

Khan, MA ;

Owais, M .

JOURNAL OF DRUG TARGETING, 2005, 13 (07) :423-429

[16] Plasmodium falciparum produces prostaglandins that are pyrogenic, somnogenic, and immunosuppressive substances in humans [J].

Kubata, BK ;

Eguchi, N ;

Urade, Y ;

Yamashita, K ;

Mitamura, T ;

Tai, K ;

Hayaishi, O ;

Horii, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (06) :1197-1202

[17] THE ROLE OF CD4+ T-CELLS IN THE PROTECTIVE IMMUNE-RESPONSE TO PLASMODIUM-CHABAUDI INVIVO [J].

LANGHORNE, J ;

SIMONHAARHAUS, B ;

MEDING, SJ .

IMMUNOLOGY LETTERS, 1990, 25 (1-3) :101-108

[18]

Langhorne J, 2002, CHEM IMMUNOL, V80, P204

[19] PROPHYLAXIS OF MURINE CANDIDIASIS VIA APPLICATION OF LIPOSOME-ENCAPSULATED AMPHOTERICIN-B AND A MURAMYL DIPEPTIDE ANALOG, ALONE AND IN COMBINATION [J].

MEHTA, RT ;

LOPEZBERESTEIN, G ;

HOPFER, RL ;

MEHTA, K ;

WHITE, RA ;

JULIANO, RL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (04) :511-513

[20]

MELANCONKAPLAN J, 1992, IMMUNOLOGY MOL BIOL, P300

← 1 2 3 4 →